Partial A1 adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation (AF)

Current Topics in Medicinal Chemistry

Volumn 4, Issue 8, 2004, Pages 839-854

  Zablocki, Jeff A ^a   Wu, Lin ^a   Shryock, John ^b   Belardinelli, Luiz ^a  

^a CV THERAPEUTICS INC   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Adenosine; Adenosine A1 receptor; Agonist; Partial; Structure activity relationship (SAR)

Indexed keywords

2' DEOXY 6 N CYCLOHEXYLADENOSINE; 2' DEOXY 6 N CYCLOPENTYLADENOSINE; 3' DEOXY 6 N CYCLOHEXYLADENOSINE; 3' DEOXY 6 N CYCLOPENTYLADENOSINE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5' DEOXY 6 N CYCLOPENTYLADENOSINE; 5' DEOXYADENOSINE; 6 N CYCLOPENTYLADENOSINE; 9 METHYLADENINE; ADENOSINE; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE DERIVATIVE; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMIC ACID DERIVATIVE; CORDYCEPIN; CVT 2759; CVT 3529; CYCLIC AMP; DEOXYADENOSINE; DIGOXIN; G PROTEIN COUPLED RECEPTOR; ISOPRENALINE; LIGAND; PHENYLISOPROPYLADENOSINE; PROPAFENONE; SOTALOL; TECADENOSON; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AREA UNDER THE CURVE; BINDING AFFINITY; CLINICAL TRIAL; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DETERMINATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; HEART ATRIUM FIBRILLATION; HEART RATE; HEART VENTRICLE; HUMAN; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; PERCEPTION; REVIEW; STRUCTURE ACTIVITY RELATION;

ADENOSINE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ENTROPY; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HEART RATE; HUMANS; LIGANDS; PROTEIN CONFORMATION; RECEPTOR, ADENOSINE A1; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3042843740     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043450998     Document Type: Review

References (51)

1. 1-adenosine receptor selectively slows AV conduction in guinea pig hearts. Am. J. Physiol. 2001, 280, H331-H343.
2. 1 receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. J. Pharmacol. Exp. Ther. 1999, 290, 702-709.
3. Kenakin, T. Agonism and Stimulus-Response Mechanisms. In Molecular Pharmacology: A Short Course; Blackwell Science, Ltd.: Oxford, England, 1997; pp 114-142.
4. 1 receptor. Biochem. Pharmacol. 1998, 56, 1287-1293.
5. 1 adenosine receptors and G proteins in phospholipid vesicles: betagamma-subunit composition influences guanine nucleotide exchange and agonist binding. Biochemistry 1997, 36, 16288-16299.
6. Kent, R. S.; De Lean, A.; Lefkowitz, R. J. A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data. Mol. Pharmacol. 1980, 17, 14-23.
7. 1 adenosine receptor-G-protein complexes: effects of receptor down-regulation and phosphorylation on coupling. Biochem. J. 1999, 338, 729-736.
8. 1 Adenosine Receptor. J. Med. Chem. 2000, 43, 250-260.
9. Lorenzen, A.; Guerra, L.; Vogt, H.; Schwabe, U. Interaction of full and partial agonists of the A1 adenosine receptor with receptor/G protein complexes in rat brain membranes. Mol. Pharmacol. 1996, 49, 915-926.
10. 1, MF-2 cells. Br. J. Pharmacol. 2000, 130, 1156-1164.
11. 1 adenosine receptor ligands. Current Topics in Medicinal Chemistry 2003, 3, 369-385.
12. Lasley, R. D. Protective effects of adenosine in reversibly and irreversibly injured ischemic myocardium. In Effects of Extracellular Adenosine and ATP on Cardiomyocytes ; Pelleg, A.; Belardinelli, L.; Eds.; Landes, Austin: Texas, 1998; pp 133-171.
13. 3 adenosine receptor agonists. J. Biol. Chem. 2000, 275, 30272-30279.
14. 1 receptor: analysis of the potential therapeutic effects obtained by its activation in the central nervous system. Curr. Med. Chem. 2002, 9, 1923-1937.
15. Sjolund, K. F.; Belfrage, M.; Karlsten, R.; Segerdahl, M.; Arner, S.; Gordh, T.; Solevi, A. Systemic adenosine infusion reduces the area of tactile allodynia in neuropathic pain following peripheral nerve injury: a multi-centre, placebo-controlled study. Eur. J. Pain 2001, 5, 199-207.
16. Merkel, L.A.; Hawkins, E.D.; Colussi, D. J.; Greenland, B. D.; Smits, G. J.; Perrone, M.H.; Cox, B. F. Cardiac and antilipolytic effects of the adenosine agonist GR79236. Pharmacology, 1995, 51, 224-236.
17. Tsang, T. S.; Gersh, B. Atrial fibrillation: an old disease, a new epidemic. Am. J. Med. 2002, 113, 432-5.
18. Haghi, D.; Schumacher, B. Current Management of Symptomatic Atrial Fibrillation. Am. J. Cardiovasc. Drugs, 2001, 1, 127-139.
19. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines and policy conferences. Circulation 2001, 104, 2118-50.
20. Wyse, D.G.; Waldo, A. L.; DiMarco, J. P.; Domanski, M. J.; Rosenberg, Y.; Schron, E. B.; Kellen, J. C.; Greene, H. L.; Mickel, M. C.; Dalquist, J. E.; Corley, S. D.; The Atrial Fibrillation Follow-up Invesigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. 2002, 347, 1825-33.
21. Wang, D.; Shryock, J. C.; Belardinelli, L. Cellular basis for the negative dromotropic effect of adenosine on rabbit single atrioventricular nodal cells. Circ. Res. 1996, 78, 697-706.
22. Endoh, M.; Maruyama, M.; Taira, N. Modification by islet-activating protein of direct and indirect inhibitory actions of adenosine on rat atrial contraction in relation to cyclic nucleotide metabolism. J. Cardiovasc. Pharmacol. 1983, 5, 131-142.
23. 1 adenosine receptor reserve for two actions of adenosine on guinea pig atrial myocytes. Mol. Pharmacol. 1997, 52, 683-691.
24. Olah, M. E.; Stiles, G. L. The role of receptor structure in determining adenosine receptor activity. Pharmacology & Therapeutics 2000, 85, 55-75.
25. Tucker, A. L.; Jia, L. G.; Holeton, D.; Taylor, A. J.; Linden, J. Dominance of G(s) in doubly Gs/Gi-coupled chimaeric A1/A2A adenosine receptors in HEK-293 cells. Biochem. J. 2000, 352, 203-210.
26. 1 receptor. Drug Design and Discovery 1992, 9, 49-67.
27. 1 adenosine receptor. J. Biol. Chem. 1999, 274, 3617-3621.
28. 2A receptor. Eur. J. Pharmacol.- Mol. Pharmacol. Sect. 1994, 268, 95-104.
29. 1 adenosine receptor action. Drug Dev. Res. 1998, 45, 93-102.
30. van der Wenden, E. M.; von Frijtag Drabbe Kuenzel, J.; Mathot, R. A. A.; Danhof, M.; IJzerman, A. P.; Soudijn, W. Ribose-modified adenosine analogs as potential partial agonists for the adenosine receptor. J. Med. Chem. 1995, 38, 4000-4006.
31. Jacobson, K. A. Adenosine (P1) and ATP (P2) receptors. In Comprehensive Medicinal Chemistry, Vol. 3, C. Hansch; Ed.; Pergamon Press: Oxford, 1990, pp. 601-642.
32. Townsend-Nicholson, A.; Schofield, P. R. A threonine residue in the seventh transmembrane domain of the human A1 adenosine receptor mediates specific agonist binding. J. Biol. Chem. 1994, 269, 2373-2376.
33. 1 receptor in vivo. Br. J. Pharmacol. 1995, 116, 1957-1964.
34. 1 receptor ligands. Life Sciences 2000, 67, 1517-1524.
35. 1 receptor ligands. Pharmaceutical Res. 1999, 16, 1054-1058.
36. Dalpiaz, A.; Townsend-Nicholson, A.; Beukers, M. W.; Schofield, P. R.; IJzerman, A. P. Thermodynamics of full agonist, partial agonist, and antagonist binding to wild-type and mutant adenosine A1 receptors. Biochem. Pharmacol. 1998, 56, 1437-1445.
37. 1 receptor ligands. Eur. J. Pharmacol.- Mol. Pharmacol. Sect. 1994, 267, 55-61.
38. Borea, P. A.; Dalpiaz, A.; Varani, K.; Gilli, P.; Gilli, G. Can thermodynamic measurements of receptor binding yield information on drug affinity and efficacy? Biochem. Pharmacol. 2000, 60, 1549-1556.
39. Bruns, R. F. Adenosine receptor activation in human fibroblasts: Nucleoside agonists and antagonists. Can. J. Physiol. Pharmacol. 1980, 58, 673-691.
40. 1 receptor. J. Med. Chem. 1998, 41, 102-108.
41. 3 Receptors. J. Med. Chem. 2001, 44, 2966-2975.
42. 1 adenosine receptor agonist (CVT-510) with diltiazem for slowing of AV nodal conduction in guinea-pig. Br. J. Pharmacol. 1999, 126, 137-146.
43. 1 agonist. Drugs of the Future 2002, 27, 846-849.
44. Zaza, A. CVT-510 (CV therapeutics). Current Opinion in Investigational Drugs 2002, 3, 96-100.
45. Lum, R. T.; Pfister, J. R.; Schow, S. R. ; Wick, M. M.; Nelson, M. G.; Schreiner, G. F.Preparation of N-6 heterocyclic substituted nucleosides as adenosine receptors PCT Int. Appl. WO 9808855 A1 (1998), pp. 28.
46. Kabell, G.; Buchanan, L. V.; Gibson, J. K.; Belardinelli, L. Effects of adenosine on atrial refractoriness and arrhythmias. Cardiovasc. Res. 1994, 28, 1385-1389.
47. 1 receptors. PCT Int. Appl. WO 0140244, (2001), p. 111.
48. 1 receptor agonists. PCT Int. Appl. WO 0140246 A1 (2001), 57 pp.
49. Shryock, J. C.; Snowdy, S.; Baraldi, P. G.; Cacciari, B.; Spalluto, G.; Monopoli, A.; Ongini, E.; Baker, S. P.; Belardinelli, L. A2A-adenosine receptor reserve for coronary vasodilation. Circulation 1998, 98, 711-718.
50. 1-adenosine receptor. Br. J. Pharmacol. 2002, 135, 1457-1466.
51. 3 adenosine receptor. J. Biol. Chem. 2002, 277, 19056-19063.